FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563385628> ?p ?o ?g. }

• W2563385628 abstract "Abstract Background CLL patients (pts) have impaired humoral and cellular immune functions, which is largely due to profound defects of T-cells. Regulation and activation of T lymphocytes depend not only on T cell receptor signaling but also on co-signaling receptors delivering either inhibitory or stimulatory signals, known as immune checkpoints. CTLA-4 (cytotoxic T lymphocyte-associated antigen-4) is transiently expressed on activated T cells, binding the same ligands as CD28, inhibiting T-cell activation. Similarly, programmed cell death protein 1 (PD-1) is expressed on activated CD4+ and CD8+ T cells inhibiting T-cell functions upon binding to the ligands B7-H1 (PD-L1, CD274) and B7-DC (PD-L2, CD273). CD137 is an inducible costimulatory receptor expressed by activated T cells. Dysregulated expression of immune checkpoint receptors on T cells of CLL pts may have an impact on T-cell responsiveness and might be a mechanism for the immune deficiency in the disease. Aim To evaluate the expression of the immune checkpoint molecules CTLA-4, PD-1 and CD137 as well as of the cell proliferation marker Ki67, the activation marker CD69 and of CD103, a marker expressed on regulatory T cells, in T cells from CLL pts in different disease phases. Methods Peripheral blood samples were obtained from 69 CLL pts and 13 healthy control donors (HD). Pts were sub-grouped according to disease phase: indolent vs progressive (i.e. fulfilling criteria for active disease). The expression of CTLA-4, PD-1, PD-L1, CD69, CD103, CD137 and Ki-67 was assessed by flow-cytometry on CD4+ and CD8+ T cells. We also analysed the change in expression of these markers on T cells after 72 hours of PHA stimulation. Results CLL pts (n=17) had a significanty higher percentage of proliferating (Ki67+) CD3+ cells compared to HD (n=7) (median 3.7% in progressive vs 1.7% in indolent CLL vs 0.9% in HD, p=0.004 and p=0.04, respectively) (Fig.1). Progressive CLL pts had a significantly higher percentage Ki67+ CD4+ compared to indolent pts as well as HD (p=0.007 and p=0.001, respectively). Both indolent and progressive pts had higher percentage of Ki67+ CD8+ T cells compared to HD (p=0.01 and p=0.03, respectively). The percentage of CTLA-4+ CD4+ and CTLA-4+ CD8+ cells was low in CLL pts as well as in HD. However, the percentage of PD-1+ CD4+ T cells was significantly higher in progressive (n=32) as compared to indolent (n=35) CLL pts (median 40.3% vs 23.3%, p<0.0001) and HD (n=13) (median 21.5%, p<0.0001) (Fig.2) and correlated positively to the white blood cell counts (WBC) at the time of testing (r=0.29, p=0.03), while no difference was found with regard to the percentage of PD-1+ CD8+ T cells. No difference was observed between CLL pts and HD regarding the expression of PD-L1 on T cells. Both the percentage of CD69+ CD4+ and CD137+ CD4+ T cells were significantly higher in progressive as compared to indolent disease and correlated positively to WBC while no difference was found seen in CD8+ T cells. The percentage of CD103+ T cells was significantly lower in progressive compared to and HD within both the CD4+ (p=0.02) and the CD8+ subpopulations (p=0.02). After 72-hrs of PHA stimulation, PD-1 and CTLA-4 expression increased in CD4+ and CD8+ cells to a similar extent in CLL pts and HD, while PD-L1 increased in HD but not in progressive CLL pts (p=0.03 and p=0.007 for CD4+ and CD8+ cells, respectively). CD69 expression increased to a similar extent in CLL pts and HD, while CD137 expression increased more in T cells from progressive pts compared to HD (p=0.03 and 0.01 for the CD4+ and CD8+ cells, respectively). No increase in CD103 on CD8+ T-cells was observed in CLL pts compared to HD (p=0.04 and p=0.01 for the indolent and progressive pts, respectively). Conclusions Progressive CLL pts have more proliferating (Ki67+) T cells in both the CD4+ and CD8+ compartments compared to HD. CD4+ T-cells in progressive CLL pts display an activated phenotype (CD69+) and express the immune co-stimulatory molecule CD137 at a significantly higher level compared to indolent pts and HD. Nevertheless, the expression of the inhibitory immune checkpoint molecule PD-1 is so high that it is reasonable to assume that these cells are heavily impaired in their immune functions. The differences observed in the expression of immune checkpoints and activation markers between CLL pts in different phases of the disease suggest that major changes occur in the CD4+ T-cell compartment during disease progression. Figure 1. Figure 1. Figure 2. Figure 2. Disclosures Hansson: Jansse Cilag: Research Funding. Österborg:Janssen, Pharmacyclics, Gilead: Consultancy, Research Funding; Novartis: Research Funding." @default.
• W2563385628 created "2017-01-06" @default.
• W2563385628 creator A5031350386 @default.
• W2563385628 creator A5048796106 @default.
• W2563385628 creator A5049924304 @default.
• W2563385628 creator A5053775708 @default.
• W2563385628 creator A5069881022 @default.
• W2563385628 creator A5070030873 @default.
• W2563385628 creator A5086327485 @default.
• W2563385628 creator A5088953410 @default.
• W2563385628 date "2015-12-03" @default.
• W2563385628 modified "2023-10-18" @default.
• W2563385628 title "T Cells from Chronic Lymphocytic Leukemia (CLL) Patients Display Dysregulated Expression of Immune Checkpoint Molecules and Activation Markers Mainly Restricted to CD4+ Cells and Correlated with Disease Activity" @default.
• W2563385628 doi "https://doi.org/10.1182/blood.v126.23.4132.4132" @default.
• W2563385628 hasPublicationYear "2015" @default.
• W2563385628 type Work @default.
• W2563385628 sameAs 2563385628 @default.
• W2563385628 citedByCount "0" @default.
• W2563385628 crossrefType "journal-article" @default.
• W2563385628 hasAuthorship W2563385628A5031350386 @default.
• W2563385628 hasAuthorship W2563385628A5048796106 @default.
• W2563385628 hasAuthorship W2563385628A5049924304 @default.
• W2563385628 hasAuthorship W2563385628A5053775708 @default.
• W2563385628 hasAuthorship W2563385628A5069881022 @default.
• W2563385628 hasAuthorship W2563385628A5070030873 @default.
• W2563385628 hasAuthorship W2563385628A5086327485 @default.
• W2563385628 hasAuthorship W2563385628A5088953410 @default.
• W2563385628 hasConcept C120642132 @default.
• W2563385628 hasConcept C147483822 @default.
• W2563385628 hasConcept C148125776 @default.
• W2563385628 hasConcept C154317977 @default.
• W2563385628 hasConcept C167672396 @default.
• W2563385628 hasConcept C202751555 @default.
• W2563385628 hasConcept C203014093 @default.
• W2563385628 hasConcept C2776090121 @default.
• W2563385628 hasConcept C2777701055 @default.
• W2563385628 hasConcept C2777938653 @default.
• W2563385628 hasConcept C2778461978 @default.
• W2563385628 hasConcept C2779118045 @default.
• W2563385628 hasConcept C2780249625 @default.
• W2563385628 hasConcept C2780851360 @default.
• W2563385628 hasConcept C502942594 @default.
• W2563385628 hasConcept C55493867 @default.
• W2563385628 hasConcept C67662055 @default.
• W2563385628 hasConcept C86803240 @default.
• W2563385628 hasConcept C8891405 @default.
• W2563385628 hasConceptScore W2563385628C120642132 @default.
• W2563385628 hasConceptScore W2563385628C147483822 @default.
• W2563385628 hasConceptScore W2563385628C148125776 @default.
• W2563385628 hasConceptScore W2563385628C154317977 @default.
• W2563385628 hasConceptScore W2563385628C167672396 @default.
• W2563385628 hasConceptScore W2563385628C202751555 @default.
• W2563385628 hasConceptScore W2563385628C203014093 @default.
• W2563385628 hasConceptScore W2563385628C2776090121 @default.
• W2563385628 hasConceptScore W2563385628C2777701055 @default.
• W2563385628 hasConceptScore W2563385628C2777938653 @default.
• W2563385628 hasConceptScore W2563385628C2778461978 @default.
• W2563385628 hasConceptScore W2563385628C2779118045 @default.
• W2563385628 hasConceptScore W2563385628C2780249625 @default.
• W2563385628 hasConceptScore W2563385628C2780851360 @default.
• W2563385628 hasConceptScore W2563385628C502942594 @default.
• W2563385628 hasConceptScore W2563385628C55493867 @default.
• W2563385628 hasConceptScore W2563385628C67662055 @default.
• W2563385628 hasConceptScore W2563385628C86803240 @default.
• W2563385628 hasConceptScore W2563385628C8891405 @default.
• W2563385628 hasLocation W25633856281 @default.
• W2563385628 hasOpenAccess W2563385628 @default.
• W2563385628 hasPrimaryLocation W25633856281 @default.
• W2563385628 hasRelatedWork W130267127 @default.
• W2563385628 hasRelatedWork W1561359004 @default.
• W2563385628 hasRelatedWork W2188177124 @default.
• W2563385628 hasRelatedWork W2336607513 @default.
• W2563385628 hasRelatedWork W2350688961 @default.
• W2563385628 hasRelatedWork W2368386037 @default.
• W2563385628 hasRelatedWork W2373867616 @default.
• W2563385628 hasRelatedWork W2376776897 @default.
• W2563385628 hasRelatedWork W2387220791 @default.
• W2563385628 hasRelatedWork W2389009787 @default.
• W2563385628 hasRelatedWork W2411314248 @default.
• W2563385628 hasRelatedWork W2413893706 @default.
• W2563385628 hasRelatedWork W2414126849 @default.
• W2563385628 hasRelatedWork W2416849578 @default.
• W2563385628 hasRelatedWork W2566148644 @default.
• W2563385628 hasRelatedWork W2577938351 @default.
• W2563385628 hasRelatedWork W2767554110 @default.
• W2563385628 hasRelatedWork W2794158301 @default.
• W2563385628 hasRelatedWork W2800269203 @default.
• W2563385628 hasRelatedWork W2921270529 @default.
• W2563385628 isParatext "false" @default.
• W2563385628 isRetracted "false" @default.
• W2563385628 magId "2563385628" @default.
• W2563385628 workType "article" @default.